Clinical Trials Directory

Trials / Sponsors / Bioverativ Therapeutics Inc.

Bioverativ Therapeutics Inc.

Industry · 12 registered clinical trials.

StatusTrialPhaseStarted
CompletedPharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
Severe Hemophilia A
Phase 32015-08-01
TerminatedFc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
Hemophilia A, Hemophilia B
—2015-07-01
CompletedStudy of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease
Healthy, Sickle Cell Disease
—2015-06-01
CompletedPharmacokinetics of rFVIIIFc at Two Vial Strengths
Severe Hemophilia A
Phase 12014-03-01
CompletedStudy to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion
Hemophilia A
Phase 32012-11-01
CompletedStudy of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Partici
Hemophilia B
Phase 32012-06-01
CompletedLong-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Tre
Severe Hemophilia B
Phase 32011-12-08
CompletedLong-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously T
Hemophilia A
Phase 32011-12-01
CompletedStudy to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVI
Severe Hemophilia A
Phase 32010-11-01
CompletedStudy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
Severe Hemophilia A
Phase 12009-12-01
CompletedStudy of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B
Severe Hemophilia B
Phase 32009-12-01
CompletedPhase I/IIa Study of FIXFc in Hemophilia B Patients
Hemophilia B
Phase 12008-04-01